Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Probiotic mixing preparation with anti-influenza capability and application thereof

A probiotic and anti-influenza technology, applied in the field of microorganisms, can solve problems such as obvious side effects, and achieve the effect of great application prospects

Active Publication Date: 2019-04-05
JIANGNAN UNIV +1
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it may be possible to start with gut microbes and try to find new drugs or methods for the prevention and treatment of influenza, so as to overcome the shortcomings of existing drugs and treatment methods with obvious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Probiotic mixing preparation with anti-influenza capability and application thereof
  • Probiotic mixing preparation with anti-influenza capability and application thereof
  • Probiotic mixing preparation with anti-influenza capability and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-1

[0065] Example 1-1: Screening and identification of Lactobacillus mucosae

[0066] 1. Filter

[0067] Taking human feces as samples, the samples were pretreated and stored in -80°C refrigerator in about 20% glycerol. After taking out and thawing, mix the samples and add 0.5mL of the sample to 4.5mL to contain 0.05% cysteine. The 0.9% normal saline was used for gradient dilution, and the appropriate gradient dilution was applied to the MRS plate with 0.05% cysteine, and cultured at 37 °C for 48 hours. A single colony was transferred to liquid MRS medium (containing 0.05% cysteine) for enrichment, and stored in 30% glycerol to obtain strain CCFM1025 and strain F1.

[0068] 2. Identification

[0069] The genomes of CCFM1025 and F1 were extracted, and the 16S rDNA of CCFM1025 and F1 was amplified and sequenced (Shanghai Sangon Bioengineering Co., Ltd.), and the sequences were compared in GenBank. The results showed that the strain was Lactobacillus mucosae, named as Lactobacill...

Embodiment 1-2

[0070] Example 1-2: Culture of Lactobacillus mucosae

[0071] Lactobacillus mucosae CCFM1025 was inserted into MRS solid medium (containing 0.05% cysteine) and cultured at 37°C for 48 hours, and the colonies were observed and observed under the microscope. The colonies were found to be Round, rough, transparent, the cells are short rod-shaped.

[0072] Lactobacillus mucosae CCFM1025 was inserted into MRS medium (containing 0.05% cysteine) and cultured at 37°C for 48h, and a growth curve was made. It is a heterofermentation that produces acid and gas from glucose.

[0073] Lactobacillus mucosae CCFM1025 was inserted into MRS medium (containing 0.05% cysteine) and cultured at 10, 15, 20, 25, 30, 35, 40, 45, and 50 °C for 48 hours, respectively, and then observed. Growth conditions, good growth at 20-35 °C, still able to grow at 45 °C, but almost no growth at 15 °C or lower than 15 °C or 50 °C.

[0074] Lactobacillus mucosae CCFM1025 was inserted into MRS medium (containing 0....

Embodiment 1-3

[0075] Example 1-3: Effects of Lactobacillus mucosae on the body weight of influenza mice

[0076] 40 healthy ICR female mice weighing 20-24g were taken and randomly divided into 5 groups. The 5 groups were named as blank control group (Control), influenza model group (Model), and ribavirin drug treatment group (Treatment). , Lactobacillus mucosae intervention group (CCFM1025) by gavage of Lactobacillus mucosae CCFM1025, Lactobacillus mucosae intervention group (F1) by gavage of Lactobacillus mucosae F1, 8 in each group.

[0077]Two weeks before the experiment, the Lactobacillus mucosae intervention group (CCFM1025) was given 10 gavage every day. 9 Lactobacillus mucosae CCFM1025 bacterial suspension dilution with the amount of CFU bacteria, Lactobacillus mucosae F1 intervention group (F1) was given the same amount of Lactobacillus mucosae F1 bacterial suspension dilution by gavage, and the other groups (Control, Model, Treatment) were given 0.2 mL per day. saline.

[0078] O...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a probiotic mixing preparation with anti-influenza capability and application thereof, and belongs to the technical fields of microorganisms and medicine. The probiotic mixingpreparation has an anti-influenza effect which is concretely shown in the aspects of (1) obviously relieving the weight loss degree of an influenza mouse; (2) obviously improving the blood index of the influenza mouse; (3) obviously relieving the respiratory tract infection inflammatory conditions of the influenza mouse; (4) obviously reducing the lung viral load quantity of the influenza mouse (obviously inhibiting the duplication and the value increase in the influenza mouse); (5) obviously enhancing the expression quantity of lung antivirus protein MxA of the influenza mouse. Therefore theprobiotic mixing preparation has huge application prospects in preparation of products for preventing and / or treating atopic dermatitis and preventing and / or treating the influenza.

Description

technical field [0001] The invention relates to a mixed preparation of probiotics with anti-influenza ability and application thereof, belonging to the technical field of microorganisms and the technical field of medicine. Background technique [0002] Influenza is often a pandemic in autumn and winter, mainly caused by influenza viruses. Influenza viruses can be divided into three types: influenza A virus, influenza B virus, and influenza C virus. Influenza in humans is mainly caused by influenza A virus and influenza B virus. Generally, animal influenza viruses do not infect humans, and human influenza viruses do not infect animals, but pigs are an exception. Pigs can be infected with both avian and human influenza viruses, but they are mainly infected with avian influenza viruses. However, once they are infected with avian influenza viruses, they can easily infect humans and cause human influenza pandemics, for example, 1819-1920 "Spanish Flu". [0003] As the most ser...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A23L33/135A61K35/745A61K35/747A61P31/16C12R1/225C12R1/01
CPCA61P31/16A23L33/135C12N1/20A61K2035/11A23V2002/00A23V2400/11A23V2400/519A23V2200/318A23V2200/30A61K35/745A61K35/747A61K2035/115A61K35/20A61K2300/00
Inventor 陈卫陆文伟翟齐啸刘馨阳赵建新杭锋张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com